Scholarlink

<p>This study reports a new therapeutic approach for canine giardiasis, the most common intestinal protozoan infection caused by <i>Giardia intestinalis</i>. It is based on the use of the probiotic strain <i>Lactobacillus johnsonii</i> CNCM I-4884 and, in particular, its bile salt hydrolase enzymatic activities. Clinical trials in dogs demonstrated that daily administration of <i>L. johnsonii</i> CNCM I-4884 significantly reduced <i>Giardia</i> cyst shedding after 14&#xa0;days. These results highlight the potential of this probiotic as a promising alternative to antimicrobials, such as nitroimidazoles or benzimidazoles, for the treatment of giardiasis in dogs. Moreover, they provide a novel approach for the veterinary industry to develop innovative products targeting this parasite. In addition to its direct anti-<i>Giardia</i> effect, <i>L. johnsonii</i> CNCM I-4884 may also act as an adjuvant therapy, supporting intestinal homeostasis, enhancing host defense mechanisms, and promoting recovery of gut balance during or after antiparasitic treatments. This dual role suggests that the strain could be considered not only as a complementary therapy but, in specific cases, as a potential stand-alone probiotic treatment for canine giardiasis.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of Lactobacillus johnsonii CNCM I-4884 on canine giardiasis: a probiotic-based approach

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月6日

查看全文
  • Bruno Polack,
  • Myriam Thomas,
  • Alejandra Wu-Chuang,
  • Lianet Abuin-Denis,
  • Alejandro Cabezas-Cruz,
  • Elsa Jacouton,
  • Mohamed Mammeri,
  • Isabelle Florent,
  • Luis G. Bermúdez-Humarán

摘要

This study reports a new therapeutic approach for canine giardiasis, the most common intestinal protozoan infection caused by Giardia intestinalis. It is based on the use of the probiotic strain Lactobacillus johnsonii CNCM I-4884 and, in particular, its bile salt hydrolase enzymatic activities. Clinical trials in dogs demonstrated that daily administration of L. johnsonii CNCM I-4884 significantly reduced Giardia cyst shedding after 14 days. These results highlight the potential of this probiotic as a promising alternative to antimicrobials, such as nitroimidazoles or benzimidazoles, for the treatment of giardiasis in dogs. Moreover, they provide a novel approach for the veterinary industry to develop innovative products targeting this parasite. In addition to its direct anti-Giardia effect, L. johnsonii CNCM I-4884 may also act as an adjuvant therapy, supporting intestinal homeostasis, enhancing host defense mechanisms, and promoting recovery of gut balance during or after antiparasitic treatments. This dual role suggests that the strain could be considered not only as a complementary therapy but, in specific cases, as a potential stand-alone probiotic treatment for canine giardiasis.

Graphical Abstract